The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
A partir de données portant sur 1 198 patients atteints d'un cancer, cette étude évalue la performance d'un système de score, basé sur 8 critères (âge inférieur à 60 ans, antécédents de nausées matinales, nombre d'heure de sommeil la nuit précédent la chimiothérapie, chimiothérapie à base de sels de platine ou d'anthracycline, ...), pour identifier les patients présentant un risque élevé de nausées ou de vomissements liés à la chimiothérapie
Background : Despite the availability of effective antiemetics and evidence-based guidelines, up to 40% of cancer patients receiving chemotherapy fail to achieve complete nausea and vomiting control. In addition to type of chemotherapy, several patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) have been identified. To incorporate these factors into the optimal selection of prophylactic antiemetics, a repeated measures cycle-based model to predict the risk of ≥ grade 2 CINV (≥ 2 vomiting episodes or a decrease in oral intake due to nausea) from day 0-5 post-chemotherapy was developed.
Patients and Methods : Data from 1 198 patients enrolled in one of five non-interventional CINV prospective studies were pooled. Generalized estimating equations were used in a backwards elimination process with the p-value set at < 0.05 to identify the relevant predictive factors. A risk scoring algorithm (range: 0-32) was then derived from the final model coefficients. Finally, a receiver operating characteristic curve (ROC) analysis was done to measure the predictive accuracy of the scoring algorithm.
Results : Over 4 197 chemotherapy cycles, 42.2% of patients experienced ≥ grade 2 CINV. Eight risk factors were identified: patient age <60 years, the first two cycles of chemotherapy, anticipatory nausea and vomiting, history of morning sickness, hours of sleep the night before chemotherapy, CINV in the prior cycle, patient self-medication with non-prescribed treatments, and the use of platinum or anthracycline-based regimens. The ROC analysis indicated good predictive accuracy with an area-under-the-curve of 0.69 (95%CI: 0.67–0.70). Prior to each cycle of therapy, patients with risk scores >16 units would be considered at high risk for developing ≥ grade 2 CINV.
Conclusions : The clinical application of this prediction tool will be an important source of individual patient risk information for the oncology clinician and may enhance patient care by optimizing the use of the antiemetics in a proactive manner.
Annals of oncology , résumé, 2016